RxDoctor Payments Data

Wendy Hanneman, MD

Family Medicine · Wausau, WINPI 1740210038

Payments from drug & device makers

$5,286in general payments, 2019–2025

Across 186 payments — averaging $28.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • AbbVie$842
  • Novo Nordisk$757
  • Pfizer$480
  • Exact Sciences$456
  • AstraZeneca$230
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$5,286100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,286 in reported general payments places this provider in the 95th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$29,836
Medicare patients
155
Services billed
341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$82,479
JardianceEmpagliflozin28$35,177
EliquisApixaban38$34,144
MounjaroTirzepatide15$16,095
TrulicityDulaglutide11$10,284
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$7,250
Levothyroxine Sodium282$2,507
Atorvastatin Calcium350$2,470
Omeprazole189$2,152
Rosuvastatin Calcium203$1,953
Albuterol Sulfate HfaAlbuterol Sulfate38$1,564
Olmesartan Medoxomil119$1,553
Propranolol Hcl ErPropranolol Hcl29$1,103
Lisinopril153$993
Simvastatin79$852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$757$82,47979 claims
Boehringer IngelheimJardiance$1,448$35,17728 claims
PfizerEliquis$480$34,14438 claims
Lilly USA, LLCMounjaro, Trulicity$224$26,37926 claims
GSKTrelegy Ellipta$43$7,25013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Wausau

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →